GlassScriptPhysician profile
Clark Butler
NPI 1841776630
$5,215.36
in general payments reported to CMS, 2019-2025
34 companies · $45.32 in 2025
The $45.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.51 · 2020: $10.97 · 2021: $376 · 2022: $1,849 · 2023: $1,453 · 2024: $1,471 · 2025: $45.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $720.21 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $671.81 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $667.35 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $570.98 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $400.26 | 2021-2024 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $270.79 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $194.48 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $165.20 | 2021-2024 | Austedo Xr, Ajovy, Austedo |
| Nevro Corp. | $149.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.44 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $124.00 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $117.73 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.05 | 2021-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $97.36 | 2022-2024 | Trintellix |
| Lundbeck LLC | $73.78 | 2024 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $72.61 | 2022-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $72.60 | 2023-2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $62.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $61.68 | 2021-2024 | Xarelto |
| Sunovion Pharmaceuticals INC. | $60.29 | 2021-2022 | |
| Exact Sciences Corporation | $47.44 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $46.44 | 2023 | Freestyle Libre 3 |
| Innovation Technologies INC | $45.32 | 2025 | Irrisept |
| E.R. Squibb & Sons, L.L.C. | $37.60 | 2022-2023 | |
| Axsome Therapeutics, INC. | $36.47 | 2023-2024 | Auvelity |
| Ardelyx, INC. | $34.71 | 2024 | Ibsrela |
| Pfizer INC. | $31.76 | 2024 | |
| Boston Scientific Corporation | $29.13 | 2023 | |
| Sanofi-Aventis U.S. LLC | $28.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $25.98 | 2022-2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $13.07 | 2024 | Voquezna |
| Sobi, INC | $12.46 | 2022 | |
| Amarin Pharma, INC. | $10.97 | 2020 | |
| Daiichi Sankyo INC. | $10.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.